ESCMID guideline for the diagnosis and management of Candida diseases 2012: Patients with HIV infection or AIDS

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL.7, 2012, Pages 68-77

  Lortholary, O ^a,b   Petrikkos, G ^c   Akova, M ^d   Arendrup, M C ^e   Arikan Akdagli, S ^d   Bassetti, M ^f   Bille, J ^g   Calandra, T ^g   Castagnola, E ^h   Cornely, O A ⁱ   Cuenca Estrella, M ^j   Donnelly, J P ^k   Garbino, J ^l   Groll, A H ^m   Herbrecht, R ⁿ   Hope, W W ^o   Jensen, H E ^p   Kullberg, B J ^k   Lass Florl C ^q   Meersseman, W ^r   Richardson, M D ^s   Roilides, E ^t   Verweij, P E ^k   Viscoli, C ^u   Ullmann, A J ^v   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HACETTEPE UNIVERSITY   (Turkey)

^e STATENS SERUM INSTITUT   (Denmark)

^f S Maria Hospital   (Italy)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h G GASLINI INSTITUTE   (Italy)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITÉ DE STRASBOURG   (France)

^o UNIVERSITY OF LIVERPOOL   (United Kingdom)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

^q INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^u UNIVERSITY OF GENOA   (Italy)

^v UNIVERSITY OF WÜRZBURG   (Germany)

more..

Author keywords

Candidiasis; Europe; Guideline; HIV AIDS

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BITTER TASTE; CANDIDA; CANDIDIASIS; CLINICAL FEATURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS CANDIDIASIS; FOLLOW UP; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MUCOCUTANEOUS CANDIDIASIS; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; SIDE EFFECT; STOMACH PH; VAGINA CANDIDIASIS; VOMITING; DRUG EFFECT; EVIDENCE BASED MEDICINE; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; PRACTICE GUIDELINE; STANDARD;

ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDA; CANDIDIASIS; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 84867691302     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12042     Document Type: Article

References (85)

1. Lortholary O, Dupont B. Fungal infections among Patients with AIDS. In: Kaufman CA, Pappas PP, Sobel JD, Dismukes WE, eds, Essential of Clinical Mycology, 2nd edn. New York: Springer, 2011; 525-536.
2. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis 1995; 21 (suppl 1): S99-S102.
3. Grabar S, Lanoy E, Allavena C et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9: 246-256.
4. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1: 47-59.
5. Kleinegger CL, Lockhart SR, Vargas K, Soll DR. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol 1996; 34: 2246-2254.
6. Fichtenbaum CJ, Koletar S, Yiannoutsos C et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30: 749-756.
7. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173: 219-225.
8. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24: 28-34.
9. Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 2002; 50: 231-240.
10. Dromer F, Improvisi L, Dupont B et al. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS 1997; 11: 1095-1101.
11. Barchiesi F, Maracci M, Radi B et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002; 50: 999-1002.
12. Sobel JD, Ohmit SE, Schuman P et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001; 183: 286-293.
13. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25: 843-846.
14. Coleman D, Sullivan D, Harrington B et al. Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis 1997; 3 (suppl 1): S96-S101.
15. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992; 73: 171-180.
16. Cuenca-Estrella M, Verweij P, Arendrup MC et al. ESCMID Diagnostic and Management Guidelines of Candida Diseases 2012: Diagnostic Procedures. Clin Microbiol Infect 2012; 18 (Suppl 7): 9-18.
17. Powderly WG, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332: 700-705.
18. Havlir DV, Dube MP, McCutchan JA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-1375.
19. Schuman P, Capps L, Peng G et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126: 689-696.
20. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997; 157: 64-69.
21. McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 1049-1056.
22. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?J Antimicrob Chemother 2006; 57: 384-410.
23. De Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989; 1: 746-748.
24. Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988; 26: 67-71.
25. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34: 2267-2268.
26. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6: 1311-1316.
27. Pons V, Greenspan D, Lozada-Nur F et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24: 1204-1207.
28. Sangeorzan JA, Bradley SF, He X et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97: 339-346.
29. Flynn PM, Cunningham CK, Kerkering T et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127: 322-328.
30. Hernandez-Sampelayo T. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13: 340-344.
31. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26: 259-272; ; quiz 273-254.
32. Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004; 35: 144-150.
33. Vazquez JA, Patton LL, Epstein JB et al. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES). HIV Clin Trials 2010; 11: 186-196.
34. Vazquez JA, Sobel JD. Miconazole mucoadhesive tablets: a novel delivery system. Clin Infect Dis 2012; 54: 1480-1484.
35. Graybill JR, Vazquez J, Darouiche RO et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33-39.
36. Phillips P, De Beule K, Frechette G et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-1373.
37. Mascarenas CA, Hardin TC, Pennick GJ, Rinaldi MG, Graybill JR. Treatment of thrush with itraconazole solution: evidence for topical effect. Clin Infect Dis 1998; 26: 1242-1243.
38. Barone JA, Koh JG, Bierman RH et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-784.
39. Cartledge JD, Midgley J, Petrou M, Shanson D, Gazzard BG. Unresponsive HIV-related oro-oesophageal candidosis - an evaluation of two new in-vitro azole susceptibility tests. J Antimicrob Chemother 1997; 40: 517-523.
40. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186.
41. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol 2000; 38: 1563-1568.
42. de Repentigny L, Ratelle J. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Chemotherapy 1996; 42: 374-383.
43. Lake-Bakaar G, Tom W, Lake-Bakaar D et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 109: 471-473.
44. Milan EP, Burattini MN, Kallas EG, Fischmann O, Costa PR, Colombo AL. Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure. Diagn Microbiol Infect Dis 1998; 32: 211-216.
45. Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991; 5: 1367-1371.
46. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27: 613-617.
47. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di Lorenzo G. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology 1996; 111: 1169-1177.
48. Laine L, Dretler RH, Conteas CN et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117: 655-660.
49. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227-232.
50. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996; 110: 1507-1514.
51. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454.
52. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27: 377-383.
53. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299.
54. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-457.
55. de Wet N, Llanos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849.
56. de Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
57. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775.
58. Vazquez JA. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl) 2010; 2: 89-101.
59. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993; 37: 2449-2453.
60. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-247.
61. Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS 2000; 14: 845-852.
62. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Intern Med 1997; 126: 332-333.
63. Eichel M, Just-Nubling G, Helm EB, Stille W. [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis]. Mycoses 1996; 39 (suppl 1): 102-106.
64. Phillips P, Zemcov J, Mahmood W et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10: 1369-76.
65. Saag M. Itraconazole oral solution: pharmacokinetics and absorption. AIDS Patient Care STDS 1997; 11 (suppl 1): S16-S17.
66. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-614.
67. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007; 8: 86-97.
68. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109, 496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 575-577.
69. Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 2000; 46: 338-340.
70. Kartsonis N, DiNubile MJ, Bartizal K, Hicks PS, Ryan D, Sable CA. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31: 183-187.
71. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004; 53: 878-881.
72. Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48: 304-309.
73. Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 1998; 17: 781-783.
74. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334: 1674-1675.
75. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990; 21: 55-60.
76. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991; 151: 2458-2464.
77. Just-Nubling G, Gentschew G, Meissner K et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991; 10: 917-921.
78. Marriott DJ, Jones PD, Hoy JF, Speed BR, Harkness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993; 158: 312-316.
79. Goldman M, Cloud GA, Wade KD et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41: 1473-1480.
80. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med 2002; 31: 169-174.
81. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 623-628.
82. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce-de-Leon S. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1, 000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore) 2003; 82: 39-50.
83. Miziara ID, Weber R. Oral candidosis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients. Oral Dis 2006; 12: 402-407.
84. Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL. Incidence of oral candidiasis and oral hairy leukoplakia in HIV-infected adults in North Carolina. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 39-47.
85. Ullmann AJ, Cornely OA, Donnelly JP et al ESCMID Diagnostic and Management Guideline for Candida Diseases 2012: Developing European Guidelines in Clinical Microbiology and Infectious Diseases 2012; 18(Suppl 7): 1-8.